$PVCT.OB Expands Protocol For Phase 1 Liver Cancer Study

Provectus issued a PR today regarding the expansion of the liver cancer Phase 1 trial. More on the study can be read here. Changes to the initial study may be found here. This trial expansion is a necessary (required) "pre-study" to the eventual Phase 2/3, since safety has not yet been established using PV-10 and sorafenib. Expanding the initial trial, rather than running another Phase 1 trial, is more efficient since the expansion merely is an extension of an already approved safety study.